

9 May 2007

Imperial Innovations Group plc (AIM: IVO), the technology commercialisation and investment company, today announces that Medical Device Innovations Ltd (MDi), a medical device development company, has acquired the exclusive rights to develop the RotaCure™ technology, a surgical instrument to repair torn rotator cuff tendons in the shoulder.

The rotator cuff is a group of four muscles in the shoulder that wrap around the shoulder joint and attach the upper arm to the shoulder blade. Injuries are common, caused either by mechanical wear or traumatic injury, such as falling on an outstretched arm, and account for about one third of cases treated at shoulder clinics throughout the developed world.

The new surgical instrument invented by Dr Anthony Bull and Dr Adam Hill, from the Department of Bioengineering and the Faculty of Medicine at Imperial College London respectively, replaces the multiple tools required by contemporary keyhole methods with a single device that the surgeon can operate with one hand. Currently, existing keyhole surgery for rotator cuff operations requires multiple instruments and incisions and great operative skill from several surgeons, taking long periods of time to execute. As a consequence of this new instrument, the surgical procedure will be greatly simplified and the number of incisions will be reduced to one or two. There is potential, with further development, for such operations to be conducted on an outpatient basis. Development of the initial prototype device has been undertaken in conjunction with J K Middleton Surgical Engineering, Wigan, Lancashire, under the direction of MDi.

Susan Searle, CEO of Imperial Innovations, said: "We are delighted to have concluded this licence deal with MDi. The RotaCure™ technology stems from world-class research at Imperial College London and we welcome the commercial backing and expertise of MDi to accelerate its development."

David Cottier, CEO Medical Device Innovations Ltd. said: "We are pleased to be collaborating with Imperial Innovations on the development of the RotaCure™ technology. This is a high potential project which combines the skill of the inventors with the project management expertise and access to funding provided by MDi. We believe that the result will be a device which significantly improves future clinical outcomes."

-Ends-

For more information contact:

Imperial Innovations

Susan Searle, Chief Executive Officer +44 (0)20 7594 6591

Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644

M:Communications

Patrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539

JP Morgan Cazenove

Steve Baldwin +44(0)20 7588 2828

Notes to Editors

About Imperial Innovations

Imperial Innovations is one of the UK's leading technology transfer and commercialisation companies. The company was founded in 1986 and its ordinary shares admitted to trading on the AIM Market of London Stock Exchange plc in July 2006, raising £26 million. The company's integrated approach encompasses the identification of ideas, protection of intellectual property, development and licensing of technology and formation, incubation and investment in technology businesses. A wide range of technologies are commercialised within the areas of healthcare, energy, environment and emerging technology trends.

Based at Imperial College London, the company has established equity holdings in 66 technology businesses and has completed 90 commercial agreements. Imperial Innovations also commercialises technologies originating from

outside Imperial College through incubation contracts with the Carbon Trust and WRAP and has relationships with a number of multinational corporations including BAE Systems.

Imperial Innovations has invested in a range of spin-out companies, including The Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited, Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, Future Waves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, Lontra Limited, Midaz Lasers Limited, NanoBioDesign Limited, Nexeon Limited, NovaThera Limited, Thiakis Limited and Veryan Medical Limited.

Imperial Innovations currently holds shares in four technology businesses now listed on AIM including the fuel cell company, Ceres Power plc.

www.imperialinnovations.co.uk

About MDi Limited

MDi is an intellectual property management and development company created to realise value from inventions made by leading surgical & biomedical engineering groups throughout Europe.

Focused exclusively on interventional medical devices, the aims of the company are to source, assess, finance and develop new technologies for commercialisation via partnerships with major healthcare corporations.

By converting ideas into products, MDi aims to improve future patient care and clinical practise whilst also enabling inventors & institutions to share in the rewards of commercialisation.

www.mdi-md.com

[Close Window](#)